Serum IL-6 as a prognostic biomarker in patients with stage IIB-III melanoma.

8545 Background: Interleukin (IL)-6 is an immunomodulatory cytokine produced by cancer cells and different immune cells. The specific function of IL-6 in cancer is unknown. Serum IL-6 is elevated in patients with different types of cancer. Elevated serum concentration of IL-6 is related to short survival in patients with stage IV melanoma. Methods: IL-6 was measured by ELISA (R&D) in pretreatment serum samples from 435 patients with stage IIB-III melanoma (151 women and 284 men, median age 51 years, range 18-77). After surgery patients were treated in a randomized study (The Nordic IFN trial) with either adjuvant interferon for 1 or 2 years, or observation. Results: Median serum concentration of IL-6 after surgery and before treatment was 1.8 ng/l, range 0.23-24 ng/l. Patients with serum IL-6 above the median had shorter overall survival (OS) compared to patients with serum IL-6 below the median (p=0.004). Median OS was 4.5 years in patients with serum IL-6 above the median (95% confidence interval (CI): 3.05-7.60). In patients with serum IL-6 below the median, median OS was not reached at the last survival-update. Multivariate Cox analysis including serum IL-6, ulceration in primary melanoma, LDH, white blood cells, lymph node metastases and Breslow thickness of primary melanoma showed that only serum IL-6 (hazard ratio (HR) = 1.48, 95% confidence interval (CI) : 1.13-1.94, p=0.004) was an independent prognostic factor for OS. In subgroup analysis of the control group and the two treatment groups, serum IL-6 demonstrated a negative prognostic impact in the control group (HR = 1.62, 95% CI: 1.02-2.57, p=0.04) and in the group treated with 2 years interferon HR = 1.69, 95% CI: 1.06-2.7, p=0.03). In the group treated with 1 year interferon this negative impact was not significant (HR = 1.15, 95% CI: 0.71-1.85, p=0.58). An interaction between IL-6 and treatment arm was not significant (p=0.45), suggesting that the negative prognostic effect of elevated pretreatment serum IL-6 is independent of treatment. Conclusions: Serum IL-6 above the median is an independent prognostic biomarker of short OS in patients operated for stage IIB-III melanoma.

Download Full-text

Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer

Cancer ◽

10.1002/cncr.25196 ◽

2010 ◽

Vol 116 (17) ◽

pp. 4114-4121 ◽

Cited By ~ 38

Author(s):

Ina Thöm ◽

Birte Andritzky ◽

Gunter Schuch ◽

Iris Burkholder ◽

Lutz Edler ◽

...

Keyword(s):

Lung Cancer ◽

Serum Concentration ◽

Cell Lung Cancer ◽

Prognostic Biomarker ◽

Nonsmall Cell Lung Cancer ◽

Poor Survival ◽

Pretreatment Serum

Download Full-text

Elevated pretreatment serum concentration of YKL-40: An independent prognostic biomarker for poor survival in patients with colorectal cancer

Medical Oncology ◽

10.1007/s12032-014-0085-6 ◽

2014 ◽

Vol 31 (8) ◽

Cited By ~ 13

Author(s):

Xiaomei Liu ◽

Yinxu Zhang ◽

Zhitu Zhu ◽

Minwen Ha ◽

Yu Wang

Keyword(s):

Colorectal Cancer ◽

Serum Concentration ◽

Prognostic Biomarker ◽

Poor Survival ◽

Pretreatment Serum

Download Full-text

Systemic Erythropoietin Concentration and its Correlation with Stage of Diabetic Retinopathy

10.21203/rs.2.12950/v1 ◽

2019 ◽

Author(s):

Sofija Davidović ◽

Babić Nikola ◽

Jovanović Sandra ◽

Barišić Sava ◽

Grković Desanka ◽

...

Keyword(s):

Diabetes Mellitus ◽

Diabetic Retinopathy ◽

Serum Concentration ◽

Proliferative Diabetic Retinopathy ◽

Elevated Serum ◽

Average Concentration ◽

Control Group ◽

Diabetic Patients ◽

Study Results ◽

Patients With Diabetes

Abstract Summary: Background: Erythropoietin (Epo) is one of systemic angiogenic factors, and its role in ocular angiogenesis and in diabetic retinopathy (DR) is not yet fully understood. Latest research data reveal possible correlation of higher EPO concentrations of erythropoietin in blood and in the eye, with more severe of stages of DR. The main aim of this work was to examine the possible influence of serum concentrations of erythropoietin on the development and stages of diabetic retinopathy in patients with diabetes mellitus type 2. Methods: The research involved 90 patients examined at University Eye Clinic in Clinical Center of Vojvodina in Novi Sad, Serbia. First group comprised of 60 patients with diabetes mellitus lasting 10 years or more, with diabetic retinopathy. Second, control group, consisted of 30 healthy individuals. In the first group of 60 diabetic patients, 30 of them had non-proliferative diabetic retinopathy (NPDR), and 30 had proliferative diabetic retinopathy (PDR). Laboratory EPO serum levels were determined, and they were correlated to the stage of DR. Concentration of EPO was assessed by ELISA method at the end of the study. Results: The highest average concentration of EPO in serum (9.95 mIU/ml) was determined in group of diabetics with PDR. The lowest average concentration of EPO in serum (6.90 mIU/ml) was found in control group. The average concentration of Epo in serum in group of diabetics with NPDR was 7.00 mIU/ml. EPO concentration in serum was elevated in group of PDR, and it was directly proportional to the level of clinical stadium of PDR, being significantly higher in moderate and severe subgroup of PDR comparing to control healthy subjects, NPDR and mild PDR (h=9.858, p=0.007). Conclusions: Significantly elevated serum concentration of EPO in advanced stages of DR, and positive correlation between EPO serum concentration and clinical stadium of PDR, suggest that erythropoietin presents one of the important growth factors from blood, which plays role in retinal ischemia and angiogenesis in diabetic retinopathy, especially in the proliferative stage of this disease. Keywords: diabetic retinopathy; erythropoietin; glycated hemoglobin; non-proliferative diabetic retinopathy; proliferative diabetic retinopathy.

Download Full-text

Serum Erythropoietin Concentration And Its Correlation With Stage Of Diabetic Retinopathy

10.21203/rs.2.12950/v3 ◽

2019 ◽

Author(s):

Sofija Davidović ◽

Babić Nikola ◽

Jovanović Sandra ◽

Barišić Sava ◽

Grković Desanka ◽

...

Keyword(s):

Diabetes Mellitus ◽

Diabetic Retinopathy ◽

Serum Concentration ◽

Proliferative Diabetic Retinopathy ◽

Elevated Serum ◽

Serum Levels ◽

Average Concentration ◽

Control Group ◽

Patients With Diabetes ◽

Advanced Stages

Abstract Erythropoietin (EPO) is one of the systemic angiogenic factors, and its role in ocular angiogenesis and in diabetic retinopathy (DR) is not yet fully understood. The latest research data reveal a possible correlation of higher erythropoietin concentrations in the blood and in the eye with the development of more advanced stages of DR. The main aim of this work was to examine the possible influence of serum concentrations of erythropoietin on the development of diabetic retinopathy in patients with diabetes mellitus type 2.Methods The research involved 90 patients examined at the University Eye Clinic of the Clinical Center of Vojvodina, Novi Sad, Serbia. The first group comprised 60 patients with diabetes mellitus lasting for ten years or more, with diabetic retinopathy. The second, control group consisted of 30 healthy individuals. In the first group of 60 patients with diabetes, 30 of them had non-proliferative diabetic retinopathy (NPDR), and 30 had proliferative diabetic retinopathy (PDR). Laboratory EPO serum levels were determined, and they were correlated to the stage of DR. Concentration of EPO was assessed by ELISA method.Results The highest average concentration of EPO in serum (9.95 mIU/ml) was determined in the group of people with diabetes with PDR. The lowest average concentration of EPO in the serum (6.90 mIU/ml) was found in the control group. The average concentration of EPO in serum in the group of patients with diabetes with NPDR was 7.00 mIU/ml. The EPO concentration in serum was elevated in the group of PDR, and it was directly proportional to the level of the clinical stadium of PDR, being significantly higher in the moderate and severe subgroup of PDR comparing to the control healthy subjects, NPDR and mild PDR (p=0.007).Conclusions Significantly elevated serum concentration of EPO in the advanced stages of DR, and positive correlation between EPO serum concentration and clinical stages of PDR, suggest that erythropoietin represents an important growth factor from blood, which plays a significant role in retinal ischemia and angiogenesis in diabetic retinopathy, especially in the proliferative stage of this disease.

Download Full-text

Serum erythropoietin concentration and its correlation with stage of diabetic retinopathy

BMC Ophthalmology ◽

10.1186/s12886-019-1240-9 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 2

Author(s):

Sofija Davidović ◽

Nikola Babić ◽

Sandra Jovanović ◽

Sava Barišić ◽

Desanka Grković ◽

...

Keyword(s):

Diabetes Mellitus ◽

Diabetic Retinopathy ◽

Serum Concentration ◽

Proliferative Diabetic Retinopathy ◽

Elevated Serum ◽

Serum Levels ◽

Average Concentration ◽

Control Group ◽

Patients With Diabetes ◽

Advanced Stages

Abstract Background Erythropoietin (EPO) is one of the systemic angiogenic factors, and its role in ocular angiogenesis and in diabetic retinopathy (DR) is not yet fully understood. The latest research data reveal a possible correlation of higher erythropoietin concentrations in the blood and in the eye with the development of more advanced stages of DR. The main aim of this work was to examine the possible influence of serum concentrations of erythropoietin on the development of diabetic retinopathy in patients with diabetes mellitus type 2. Methods The research involved 90 patients examined at the University Eye Clinic of the Clinical Center of Vojvodina, Novi Sad, Serbia. The first group comprised 60 patients with diabetes mellitus lasting for 10 years or more, with diabetic retinopathy. The second, control group consisted of 30 healthy individuals. In the first group of 60 patients with diabetes, 30 of them had non-proliferative diabetic retinopathy (NPDR), and 30 had proliferative diabetic retinopathy (PDR). Laboratory EPO serum levels were determined, and they were correlated to the stage of DR. Concentration of EPO was assessed by ELISA method. Results The highest average concentration of EPO in serum (9.95 mIU/ml) was determined in the group of people with diabetes with PDR. The lowest average concentration of EPO in the serum (6.90 mIU/ml) was found in the control group. The average concentration of EPO in serum in the group of patients with diabetes with NPDR was 7.00 mIU/ml. The EPO concentration in serum was elevated in the group of PDR, and it was directly proportional to the level of the clinical stadium of PDR, being significantly higher in the moderate and severe subgroup of PDR comparing to the control healthy subjects, NPDR and mild PDR (p = 0.007). Conclusions Significantly elevated serum concentration of EPO in the advanced stages of DR, and positive correlation between EPO serum concentration and clinical stages of PDR, suggest that erythropoietin represents an important growth factor from blood, which plays a significant role in retinal ischemia and angiogenesis in diabetic retinopathy, especially in the proliferative stage of this disease.

Download Full-text

Increased Serum Level and High Tissue Immunoexpression of Interleukin 17 in Cutaneous Lichen Planus: A Novel Therapeutic Target for Recalcitrant Cases?

Disease Markers ◽

10.1155/2020/6521274 ◽

2020 ◽

Vol 2020 ◽

pp. 1-7

Author(s):

Magdalena Żychowska ◽

Aleksandra Batycka-Baran ◽

Wojciech Baran

Keyword(s):

Serum Level ◽

Serum Concentration ◽

Healthy Volunteers ◽

Lichen Planus ◽

Elevated Serum ◽

Tissue Expression ◽

Enzyme Linked Immunosorbent Assay ◽

Control Group ◽

Interleukin 17 ◽

Tissue Samples

Background. Interleukin-17 is supposed to play an important role in the pathogenesis of oral lichen planus (OLP). However, there is scarce data in the literature on its significance in the cutaneous variant of the disease. Objectives. To determine the serum level and tissue immunoexpression of IL-17 in cutaneous lichen planus (CLP). Methods. Fifty-two adult patients with CLP, without any significant autoimmune or inflammatory conditions, were included in the first part of the study. The control group consisted of 27 age- and sex-matched healthy volunteers. Serum concentration of IL-17 was quantified using enzyme-linked immunosorbent assay (ELISA) kit. In the second part of the study, the tissue expression of IL-17 was assessed in archival paraffin-embedded biopsy specimens from CLP (n=14) against normal control tissues (n=11) using immunohistochemical assays. The expression was evaluated using Zeiss Axio Imager A2 light microscope. Positively stained cells were counted in 10 fields of view for biopsy specimen at 200x magnification, and the mean value was calculated. Results. The serum level of IL-17 was significantly elevated in patients with CLP, compared with healthy volunteers (0.218±0.221 ng/ml versus 0.126±0.058 ng/ml, respectively; p=0.025). No correlation was found between the serum concentration of IL-17 and patient age, gender, disease duration, extent of skin involvement, the presence or intensity of pruritus, and coexistence of mucosal lesions. In tissue samples from CLP lesions, significantly higher numbers of cells expressing IL-17 were found when compared to a healthy skin (p<0.001). Conclusion. Elevated serum concentration of IL-17 and high expression in a lesional skin support the hypothesis that IL-17 is implicated in the immunopathogenesis of CLP. These findings may constitute a premise for the future use of anti-IL-17 monoclonal antibodies in the treatment of severe and recalcitrant forms of CLP.

Download Full-text

Lipoprotein(a) in Chronic Renal Failure

Journal of Medical Biochemistry ◽

10.2478/v10011-009-0004-0 ◽

2009 ◽

Vol 28 (2) ◽

pp. 82-88

Author(s):

Velibor Čabarkapa ◽

Mirjana Đerić ◽

Zoran Stošić ◽

Vladimir Sakač ◽

Sunčica Kojić-Damjanov ◽

...

Keyword(s):

Renal Failure ◽

Renal Function ◽

Chronic Renal Failure ◽

Serum Concentration ◽

Elevated Serum ◽

Serum Levels ◽

Chronic Hemodialysis ◽

Control Group ◽

Elevated Concentration ◽

Lipoprotein A

Lipoprotein(a) in Chronic Renal Failure Cardiovascular diseases are the leading cause of mortality in patients with chronic renal failure. Among the parameters contributing to cardiovascular disease development is the elevated serum concentration of lipoprotein(a) diagnosed in these patients, especially in the terminal stage of CRF. However, an elevated concentration of lipoprotein(a) could influence the renal failure progression. The objective of this study is to examine the lipoprotein(a) serum levels in chronic renal failure, and to establish the relation between the stage of renal function preservation and the level of this lipoprotein. In this study 127 subjects were included, divided into three groups. The first group contained 42 subjects (15 females and 27 males) in different CRF stages, the second group contained 32 subjects (7 females and 25 males) on a chronic hemodialysis program, and the control group contained 53 subjects (22 females and 31 males) with regular renal function. The results obtained point to significantly higher frequency of hyper-Lp(a) lipoproteinaemia in dialysed patients compared to the control group, as well as significantly higher Lp(a) values in both groups of patients compared to the control group. It can be concluded that for the risk assessment of premature atherosclerotic changes, but also renal failure progression in patients with CRF, determination of the Lp(a) serum concentration is recommendable.

Download Full-text

The toxic effects of ammonia on growth rate and some blood parameters in common carp (Cyprinus carpio L.)

Al-Anbar Journal of Veterinary Sciences ◽

10.37940/ajvs.2018.11.1.13 ◽

2018 ◽

Vol 11 (1) ◽

pp. 109-113

Author(s):

Q Jumaa ◽

K Al-Saeedy ◽

W Obid

Keyword(s):

Treatment Group ◽

Common Carp ◽

Blood Cells ◽

Negative Impact ◽

White Blood Cells ◽

Hemoglobin Concentration ◽

Blood Parameters ◽

Control Group ◽

Common Carp Cyprinus Carpio ◽

Fish Breeding

This study was performed to know the effect of ammonia on the blood picture and the weight of common carp fish. 50 fish were used at the age of 6 months and were divided into two groups. Each group included 25 fish. The first group represented the treatment group with ammonia at a concentration of 1.0 mg/ L. and the second group represented control group. It is grown in plastic basins with dimensions of 1.5 × 2 meters and continued treatment for four weeks. It was observed that the weight in the ammonium treatment group had the lowest significant value (p≤0.05) compared to the control group. It was also observed in this study that the ammonia group had the lowest significant values in (white blood cells, red blood cells, hemoglobin concentration and Packed cell volume) compared with control group. As for the biochemical parameters, it was observed that the Glucose concentration and each of the enzymes Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) had a record the highest value in the group treated with ammonia compared with the control group while the total protein recorded the lowest significant value in the group treated with ammonia Compared to control group. We conclude from this study that increasing the concentration of ammonia in the aquatic environment has a negative impact on fish breeding and health.

Download Full-text